Get the Stockscreener App
4.23
2.17%
0.09
Jasper Therapeutics Inc stock is traded at $4.23, with a volume of 210.96K.
It is up +2.17% in the last 24 hours and down -28.67% over the past month.
See More
Previous Close:
$4.14
Open:
$4.08
24h Volume:
210.96K
Relative Volume:
0.42
Market Cap:
$62.19M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-0.6839
EPS:
-6.1852
Net Cash Flow:
$-52.33M
1W Performance:
-9.62%
1M Performance:
-28.67%
6M Performance:
-75.13%
1Y Performance:
-83.85%
1-Day Range:
$4.05
$4.38
1-Week Range:
$4.05
$4.95
52-Week Range:
$4.05
$30.70
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
4.23 | 62.19M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | UBS | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Sep-09-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-08-24 | Initiated | BTIG Research | Buy |
| Jun-27-24 | Initiated | Stifel | Buy |
| May-06-24 | Initiated | H.C. Wainwright | Buy |
| Apr-03-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-18-24 | Initiated | TD Cowen | Outperform |
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
JSPR stock touches 52-week low at $4.54 amid market challenges By Investing.com - Investing.com South Africa
JSPR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia
Jasper Therapeutics Inc Files For Common Stock Offering Of Up To $100 MillionSEC Filing - MarketScreener
DBV Technologies (NASDAQ:DBVT) vs. Jasper Therapeutics (NASDAQ:JSPR) Head to Head Comparison - Defense World
Jasper Therapeutics inks new sales agreement, ends previous deal By Investing.com - Investing.com South Africa
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $62.50 - Defense World
Jasper Therapeutics inks new sales agreement, ends previous deal - Investing.com
Jasper Therapeutics Files $300 Million Mixed Shelf -March 19, 2025 at 05:08 pm EDT - Marketscreener.com
Jasper Therapeutics Signs New Sales Agreement with Jefferies - TipRanks
Jasper Therapeutics terminates Cantor sales agreement -March 19, 2025 at 04:53 pm EDT - Marketscreener.com
Jasper Therapeutics files for mixed shelf offering of up to $300 mln -March 19, 2025 at 04:17 pm EDT - Marketscreener.com
(JSPR) On The My Stocks Page - news.stocktradersdaily.com
Jasper Therapeutics’ (JSPR) Buy Rating Reiterated at HC Wainwright - Defense World
Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics - TipRanks
FY2025 EPS Estimates for JSPR Raised by Cantor Fitzgerald - Defense World
Oppenheimer maintains $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Stifel maintains Buy rating, $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Positive Outlook for Jasper Therapeutics: Buy Rating Affirmed on Promising BEACON Study Data and Strategic Milestones - TipRanks
Jasper Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Equities Analysts Set Expectations for JSPR Q1 Earnings - Defense World
Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study - MSN
JSPRJasper Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Jasper Therapeutics Presents Updated Clinical Data on Briquilimab at AAAAI 2025 Annual Meeting - Nasdaq
Jasper Therapeutics Presents Clinical and Preclinical - GlobeNewswire
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - Yahoo Finance UK
Promising Outlook for Jasper Therapeutics: Buy Rating Backed by Briquilimab’s Clinical Progress and Financial Stability - TipRanks
Jasper Therapeutics Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Jasper Therapeutics, Inc. SEC 10-K Report - TradingView
Jasper Therapeutics to present briquilimab study at AAD Meeting - Investing.com India
Jasper Therapeutics to present briquilimab study at AAD Meeting By Investing.com - Investing.com South Africa
Jasper Therapeutics Announces Late-Breaking Briquilimab - GlobeNewswire
Can Jasper's Briquilimab Data for Chronic Urticaria Transform Treatment Outcomes? - StockTitan
Jasper Therapeutics Reports Promising Clinical Progress - TipRanks
Jasper Therapeutics: Strategic Advancements and Promising Clinical Efficacy Drive Buy Rating - TipRanks
Promising Data from Jasper Therapeutics’ BEACON and SPOTLIGHT Studies Justify Buy Rating for Briquilimab - TipRanks
Jasper Therapeutics reports Q4 EPS ($1.62), consensus ($1.23) - TipRanks
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings To Watch: Life Time (LTH) Reports Q4 Results Tomorrow - The Globe and Mail
Jasper Therapeutics to Present at Upcoming March Investor Conferences - The Manila Times
Jasper Therapeutics Sets March Conference Circuit to Showcase Mast Cell Disease Breakthroughs - StockTitan
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential reshapes CSU stock outlook - Investing.com
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes CSU stock outlook - Investing.com India
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $64.44 Consensus PT from Analysts - Defense World
Learn to Evaluate (JSPR) using the Charts - Stock Traders Daily
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
What To Expect From RE/MAX’s (RMAX) Q4 Earnings - The Globe and Mail
Jasper Therapeutics stock holds $70 target at JMP Securities By Investing.com - Investing.com Canada
Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Down 11.1% in January - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from Analysts at UBS Group - MarketBeat
UBS Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation - Nasdaq
JSPR stock touches 52-week low at $5.22 amid market challenges - Investing.com Nigeria
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):